JakubSvobodaMD

PubMed

• Prolonged neurologic symptoms following immune effector cell-associated neurotoxicity syndrome in patients with large B cell lymphoma treated with chimeric antigen rec...
  Luke Maillie, Sunita D Nasta, Jakub Svoboda, Stefan K Barta, Elise A Chong
  Transplantation and Cellular Therapy. 2025-01-21
• Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies.
  Julie K Jadlowsky, Elizabeth O Hexner, Amy Marshall, Stephan A Grupp, Noelle V Frey
  Nature Medicine. 2025-01-20
• Analysis of Histologic, Immunohistochemical and Genomic Features of Large B Cell Lymphoma Tumors May Predict Response to Polatuzumab Vedotin Based Therapy in Patients ...
  Michael Schneider, Sunita D Nasta, Stefan K Barta, Elise A Chong, Jakub Svoboda
  Clinical Lymphoma, Myeloma & Leukemia. 2025-01-01

Journal Articles

• Five-Year Follow-up of Lenalidomide plus Rituximab as Initial Treatment for Mantle Cell Lymphoma  
  Jia Ruan, Jakub Svoboda, John P Leonard, Sonali M Smith, Morton Coleman, Richard R Furman, Blood
• Real World Outcomes and Management Strategies for Venetoclax-Treated Chronic Lymphocytic Leukemia Patients in the United States  
  Arun K Singavi, Andrew Zelenetz, Nicole Lamanna, Bruce D Cheson, Richard R Furman, Jakub Svoboda, Stephen J Schuster, John N Allan, Chaitra S Ujjani, Haematologica
• Non-Viral RNA Chimeric Antigen Receptor Modified T Cells in Patients with Hodgkin Lymphoma  
  Stephan A Grupp, Sunita Dwivedy Nasta, Susan R Rheingold, Daniel J Landsburg, Carl H June, Jakub Svoboda, Stephen J Schuster, Saar I Gill, David L Porter, Bruce L Levine, Blood

Abstracts/Posters

• Outcomes in Aggressive B-Cell Non-Hodgkin Lymphomas with Anti-CD19 CAR T-Cell (CTL019) Products Not Meeting Commercial Release Specifications
  Jakub Svoboda, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death 1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classic...
  Jakub Svoboda, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Outcome of Autologous Stem Cell Transplantation Following PD-(L)1 Based Salvage Therapy for Multiply Relapsed Patients with Classic Hodgkin Lymphoma
  Jakub Svoboda, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Impact of Novel Agents on Outcomes of Patients with Classical Hodgkin Lymphoma and Primary Treatment Failure
  Jakub Svoboda, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Identification and Validation of Predictive Biomarkers to CD19- and BCMA-Specific CAR T-Cell Responses in CAR T-Cell Precursors
  Jakub Svoboda, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• A Characterization of Bridging Therapies Leading up to Commercial CAR T-Cell Therapy
  Jakub Svoboda, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Concurrent Use of Novel Agents and Radiation Is Tolerated in Lymphoma Patients
  Jakub Svoboda, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Fitness and Anthracycline Use in Front-Line Therapy for Older Patients with Classical Hodgkin Lymphoma: A US Multi-Center Retrospective Analysis
  Jakub Svoboda, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Hospitalization Patterns with Commercial CAR T-Cell Therapy: A Single Institution Experience
  Jakub Svoboda, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Reponse-Adapted Study of Ibrutinib with Temozolomide, Etoposide, Doxil, Dexamethasone, and Rituximab (TEDDI-R) in Aggressive B-Cell Lymphomas with Secondary Involvemen...
  Jakub Svoboda, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Outcomes for Double Hit Lymphoma Patients Identified Via Routine Vs Selective Testing for MYC Rearrangement
  Jakub Svoboda, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Pembrolizumab and Copanlisib for the Treatment of Relapsed or Refractory Mature T-Cell Lymphomas
  Jakub Svoboda, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• Health-Related Quality-of-Life Outcomes in Patients with Classical Hodgkin Lymphoma: A Prospective, Observational Study in US Oncology Practices 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Current Selection Patterns, Toxicities and Outcomes of Pre-Transplant Salvage Treatment Regimens in Patients with Relapsed/Refractory Hodgkin Lymphoma: Results of a Mu... 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Use of Bendamustine for Lymphodepletion before Tisagenlecleucel (anti-CD19 CAR T cells) for Aggressive B-Cell Lymphomas 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Pembrolizumab in Patients with Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): Data from the Keynote-013 and Keynote-170 StudiesClinically Re... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Clinical Outcomes of Venetoclax Therapy in Patients with Relapsed/Refractory (r/r) Non Hodgkin Lymphomas (NHL) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Join now to see all